Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
AstraZeneca
Chubb
Chinese Patent Office
Harvard Business School
Accenture
Julphar
Fish and Richardson
Dow

Generated: February 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,500,829

« Back to Dashboard

Which drugs does patent 6,500,829 protect, and when does it expire?

Patent 6,500,829 protects FUSILEV and is included in one NDA.

This patent has twenty-one patent family members in nine countries.
Summary for Patent: 6,500,829
Title: Substantially pure diastereoisomers of tetrahydrofolate derivatives
Abstract:The present invention related to the preparation of substantially pure diastereoisomers of derivatives of tetrahydrofolate and the use of such diastereoisomers. More particularly the present invention provides a process for the preparation of a desired substantially pure (6R or 6S) diastereoisomer of a derivative of tetrahydrofolic acid or salt or ester. The process comprises the steps of: attaching a chiral auxiliary group at either N-5 or N-10 of a mixture of 6R and 6S diastereoisomers of tetrahydrofolic acid, separating the new diastereoisomers, recovering the desired new diastereoisomer (6R or 6S) corresponding to the desired (6R or 6S) diastereoisomer, and converting the substantially pure new diastereoisomer recovered into the corresponding diastereoisomer.
Inventor(s): Wood; Hamish Christopher Swan (Glasgow, GB), Suckling; Colin James (Glasgow, GB), Rees; Lilias G. (Glasgow, GB)
Assignee: University of Strathclyde (Glasgow, GB)
Application Number:08/426,458
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 6,500,829

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Spectrum Pharms FUSILEV levoleucovorin calcium POWDER;IV (INFUSION) 020140-001 Mar 7, 2008 AP RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Spectrum Pharms FUSILEV levoleucovorin calcium SOLUTION;IV (INFUSION) 020140-002 Apr 29, 2011 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Spectrum Pharms FUSILEV levoleucovorin calcium SOLUTION;IV (INFUSION) 020140-003 Apr 29, 2011 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,500,829

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom8621268Sep 03, 1986

Non-Orange Book US Patents Family Members for Patent 6,500,829

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
4,959,472 Process for preparing substantially pure diastereoisomers of tetrahydrofolic derivatives ➤ Try a Free Trial
6,849,628 Optically active compounds ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,500,829

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 230746 ➤ Try a Free Trial
Austria 231150 ➤ Try a Free Trial
Austria 295173 ➤ Try a Free Trial
Australia 598024 ➤ Try a Free Trial
Australia 7777587 ➤ Try a Free Trial
Canada 1339368 ➤ Try a Free Trial
Germany 3752361 ➤ Try a Free Trial
Germany 3752362 ➤ Try a Free Trial
Germany 3752384 ➤ Try a Free Trial
European Patent Office 0266042 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Argus Health
Chubb
Cerilliant
Daiichi Sankyo
Mallinckrodt
Medtronic
Citi
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot